• 1.西安交通大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院普外科(西安 710061);;
  • 2.西安交通大學(xué)醫(yī)學(xué)院第一附屬醫(yī)院麻醉科;

目的探討胃腸道間質(zhì)瘤(GIST)的診斷與治療。
方法對我院1999年1月至2004年12月收治的48例GIST患者的病理特點及外科治療進行回顧性分析。
結(jié)果本組GIST發(fā)生部位: 胃29例(60.4%),小腸11例(22.9%)，結(jié)腸3例(6.3%),直腸4例(8.3%),肛管1例(2.1%)。主要臨床表現(xiàn)為消化道出血(52.1%)和腹部腫塊(35.4%)，免疫組化表型CD117陽性率為83.3%(40/48),CD34陽性率為77.1%(37/48),SMA陽性率為27.1%(13/48),S100陽性率為22.9%(11/48)。48例均行手術(shù)切除。全組術(shù)后均未行放、化療，隨訪12~60個月，平均35個月，隨訪率為100%。良性及交界性患者均無復(fù)發(fā)； 13例惡性者中6例復(fù)發(fā)，其中5例死亡。
結(jié)論GIST在中老年人中好發(fā), 部位以胃及小腸最多見，以消化道出血、腹部腫塊表現(xiàn)為主。腫瘤的大小是GIST良、惡性的重要臨床指標。GIST的診斷有賴于病理形態(tài)學(xué)檢查與免疫組化的結(jié)合。完整的局部手術(shù)切除是最有效的治療手段。

引用本文： 霍雄偉,馬清涌,高燕鳳,孫學(xué)軍,劉浩,盛薇,許延發(fā),石景森. 胃腸道間質(zhì)瘤臨床診治分析（附48例報告）. 中國普外基礎(chǔ)與臨床雜志, 2006, 13(4): 441-443. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Hum Pathol, 2001; 32(6)∶578.
2. Am J Surg Pathol, 1983; 7(6)∶507.
3. The histopathological differential diagnosis of gastrointestinal stromal tumours [J].
4. J Clin Pathol, 2001; 54(2)∶96.
5. Prognosis of gastrointestinal smoothmuscle (stromal) tumors: dependence on anatomic site [J].
6. Am J Surg Pathol, 1999; 23(1)∶82.
7. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival [J].
8. Ann Surg, 2000; 231(1)∶51.
9. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours [J].
10. Br J Surg, 2003; 90(3)∶332.
11. N Engl J Med, 2002; 347(7)∶472.
12. 紀小龍, 虞積耀. 胃腸道間質(zhì)瘤 [J]. 診斷病理學(xué)雜志, 2000; 7(1)∶3.
13. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis [J].
14. Miettinen M, Lasota J. Gastrointestinal stromal tumors——definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis [J]. Virchows Arch, 2001; 438(1)∶1.
15. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors [J]. Am J Surg Pathol, 1999; 23(4)∶377.
16. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC.
17. Emory TS, Sobin LH, Lukes L, et al.
18. 席呂剛, 蔡端. 胃腸道間質(zhì)瘤35例診治分析 [J]. 中國實用外科雜志, 2005; 25(3)∶151.
19. 周雷, 王巖, 姚力, 等. 胃腸道間質(zhì)瘤的診治及臨床病理分析 [J]. 中華普通外科雜志, 2003; 18(1)∶45.
20. DeMatteo RP, Lewis JJ, Leung D, et al.
21. Langer C, Gunawan B, Schuler P, et al.
22. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
23. Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop [J].
  1. 1. Hum Pathol, 2001; 32(6)∶578.
  2. 2. Am J Surg Pathol, 1983; 7(6)∶507.
  3. 3. The histopathological differential diagnosis of gastrointestinal stromal tumours [J].
  4. 4. J Clin Pathol, 2001; 54(2)∶96.
  5. 5. Prognosis of gastrointestinal smoothmuscle (stromal) tumors: dependence on anatomic site [J].
  6. 6. Am J Surg Pathol, 1999; 23(1)∶82.
  7. 7. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival [J].
  8. 8. Ann Surg, 2000; 231(1)∶51.
  9. 9. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours [J].
  10. 10. Br J Surg, 2003; 90(3)∶332.
  11. 11. N Engl J Med, 2002; 347(7)∶472.
  12. 12. 紀小龍, 虞積耀. 胃腸道間質(zhì)瘤 [J]. 診斷病理學(xué)雜志, 2000; 7(1)∶3.
  13. 13. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis [J].
  14. 14. Miettinen M, Lasota J. Gastrointestinal stromal tumors——definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis [J]. Virchows Arch, 2001; 438(1)∶1.
  15. 15. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors [J]. Am J Surg Pathol, 1999; 23(4)∶377.
  16. 16. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC.
  17. 17. Emory TS, Sobin LH, Lukes L, et al.
  18. 18. 席呂剛, 蔡端. 胃腸道間質(zhì)瘤35例診治分析 [J]. 中國實用外科雜志, 2005; 25(3)∶151.
  19. 19. 周雷, 王巖, 姚力, 等. 胃腸道間質(zhì)瘤的診治及臨床病理分析 [J]. 中華普通外科雜志, 2003; 18(1)∶45.
  20. 20. DeMatteo RP, Lewis JJ, Leung D, et al.
  21. 21. Langer C, Gunawan B, Schuler P, et al.
  22. 22. Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
  23. 23. Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop [J].